Mobileye Global Inc.

Executive Summary

SELL, Low conviction. Rated SELL, Low conviction. Mobileye has real strengths, including zero debt, positive FCF, repeated EPS beats, and a much higher FY26 adjusted operating income outlook, but the stock still prices in a cleaner growth path than the company is showing. With Q3 revenue guided down 5% to 6% YoY, ASP pressure from China mix, and SuperVision stepping down in 2H, the setup still skews downside despite the stock already being 51.9% below its 52-week high.

Investment Thesis

The stock is cheap versus its own history, not versus its current earning path. At $7.61, MBLY trades 51.9% below its 52-week high and 84.2% below its 5-year high, which is exactly why it is tempting. But the current business does not yet support the autonomy optionality still embedded in a 3.2x sales multiple. FY2025 revenue was $1.9B, up just 2.9%, and the company still posted EPS of -$0.48 with a -167.5% operating margin under GAAP. That is not a profile that deserves a large premium to peers at 1.1x sales unless growth is about to accelerate decisively.

The core issue is that volume is healthy, while monetization is not. Q2 showed 10M EyeQ units, above expectations, but revenue was only $508M because ASP disappointed due to China export mix. That tension continues in guidance. Management raised the FY26 revenue midpoint to $1.995B, but also guided Q3 revenue down 5% to 6% YoY on 9.3M to 9.5M units. In other words, units are not the problem. Pricing and mix are. If the company cannot turn rising penetration into stronger dollar growth, the market will keep treating it as a component supplier with autonomy optionality, not as a pure autonomy platform.

The second issue is quality of profit. The FY26 adjusted operating income midpoint jumped to $395M from $210M, which is a real improvement, but $180M to $200M of that comes from the R&D incentive benefit. That matters because investors should pay less for incentive-assisted profit than for durable product-driven gross margin expansion. Management itself flagged that Q3 incentive contribution will drop materially from Q2 because of the retroactive catch-up. The earnings power is improving, but the path is not as clean as the headline suggests.

What keeps this from being a high-conviction short is the balance sheet and the installed-base franchise. Mobileye has no debt, FCF of $0.1B, a 4.60 current ratio, and a strong innovation score. It is also beating Street EPS expectations consistently, and the Stellantis cloud-enhanced ADAS win points to a real 2027 ASP tailwind if execution holds. That upside is real, but it belongs to the bull case, not the base case. At this price, the market is still paying too much for that future while the near-term numbers are saying wait.

Key Metrics

Financial Strength

Financial risk is not the problem here. Mobileye carries no debt, has a 4.60 current ratio, and remains FCF positive at $0.1B, which gives it the ability to absorb uneven auto demand and keep funding ADAS and autonomy programs. The margin story is more nuanced: reported FY2025 margins remain deeply negative, but underlying profitability is clearly improving, especially with the FY26 adjusted operating income lift. The concern is that a large piece of that improvement comes from incentives rather than clean revenue quality, so the balance sheet is strong enough to wait, but not enough on its own to justify paying a premium multiple today.

Competitive Position

Mobileye's moat is its long-standing relationships with global OEMs, its EyeQ silicon and vision stack, and the scale of data and validation from tens of millions of deployed ADAS units. That moat is still meaningful in mainstream ADAS, where design cycles are long and safety validation matters. Durability is less certain in higher-level autonomy over the next few years because OEMs are increasingly willing to in-source software, and AI tools can compress some software differentiation unless Mobileye keeps winning integrated hardware-plus-software programs with higher ASP.

Management & Guidance

Management's latest guidance is directionally better, but the composition matters. CFO Moran Rojansky said, "We are increasing the full year revenue outlook to $1.995 billion at midpoint and tightening the range, implying 4% to 7% revenue growth across the range." He also said, "We are increasing our outlook for adjusted operating income to $395 million at the midpoint, up from $210 million in the prior outlook." That upgrade deserves credit, especially after repeated EPS beats, but credibility is mixed because near-term guidance still includes Q3 revenue down 5% to 6% YoY, and management flagged weaker 2H SuperVision shipments plus timing slips into 2027. Net: management is credible on cost control and near-term earnings mechanics, less so on clean advanced-product timing.

Segment Analysis

• ADAS / EyeQ core business (Majority of revenue, exact split not disclosed in provided data): Driven by 10M Q2 EyeQ units and 39M+ FY26 expected units, with growth from OEM share gains and emerging-market fitment offset by lower ASP.
• SuperVision and advanced systems (Minority of revenue, exact split not disclosed in provided data): Near-term headwind as 2H SuperVision shipments step down on inventory consumption and sample timing slips to 2027.
• Robotaxi / Moovit (Immaterial revenue contribution currently): Moovit is reducing B2B headcount as Mobileye shifts to a vertically integrated robotaxi strategy targeting 2027 launch in at least one U.S. city.
• Geography (Not disclosed in provided data): China remains important to mix and pricing, with current downside from higher China OEM export volume lowering ASP, while Stellantis supports future non-China ASP uplift from 2027.

Capital Allocation

Capital allocation is conservative and mostly sensible. The company has $0.0B debt, generated $0.1B FCF, and reported essentially $0.0B capex, which fits a fabless, IP-heavy model. Shareholder returns are minimal at the aggregate annual level, but management did repurchase $24M of stock in Q2 at an average $9.37, above the current price, and said the pace should grow or hold through the year; that is supportive, though too small to change the thesis.

Management Execution & Track Record

Execution has been mixed, but better on cost and near-term earnings than on growth quality. On the 2024 Q3 call, management said FY24 revenue would be $1.64B to $1.66B, adjusted operating income $175M to $185M, and that 2025 would bring revenue growth and higher operating cash flow, while 2025 OpEx would be held at or below the Q3 level on average after the LiDAR closure. Since then, FY2025 revenue reached $1.9B, up 2.9% YoY, and FY2026 revenue guidance has moved to $1.97B to $2.02B, so the basic growth call was directionally right, but not strong enough to justify a premium multiple. Management also said programs such as EyeQ6 High, imaging radar, VW SuperVision/Chauffeur and robotaxi were on track for launches from the back half of 2026 onward; today, the more important update is that 2H SuperVision shipments are stepping down and sample timing has slipped to 2027, which is a miss on timing quality. Against that, the company has beaten EPS estimates in 8 straight quarters, and the FY26 adjusted operating income midpoint was lifted to $395M from $210M, so management deserves credit on operating discipline and extracting incentive benefits, even if advanced-product timing remains less reliable.

Positioning & Flows

Ownership is not crowded, with the top three institutions holding 18.3% and insiders at 4.0%, which limits forced unwind risk but also means less obvious sponsorship support. Short interest is moderate at 6.35%, or 36.8M shares, with 6 days-to-cover, enough for event volatility but not a classic squeeze setup. Options positioning is not supportive, with negative gamma and zero-gamma at $7.87, slightly above spot, which can amplify downside if the stock stays below that level.

Bull Case

• Q2 2026 revenue of $508M was roughly flat YoY, but 10M EyeQ units beat expectations, showing OEM share gains and better ADAS fitment despite weak auto production.
• Management sharply raised FY26 adjusted operating income to $370M to $420M, with midpoint $395M versus prior outlook $210M, helped by an R&D incentive benefit of $180M to $200M that management says appears sustainable into future years.
• Balance sheet risk is low, with debt/equity 0.00, total debt $0.0B, current ratio 4.60, and FCF of $0.1B, giving the company room to keep investing through a choppy auto cycle.
• Execution versus near-term Street expectations has been solid, with 8 straight quarterly EPS beats through 2026-07-23, including +235.7%, +42.6%, and +21.0% surprises in the last seven reported quarters.

Bear Case

• The near-term revenue profile is weak. Management explicitly guided Q3 FY26 revenue down 5% to 6% YoY, even after raising the full-year midpoint to $1.995B, which implies growth is still uneven and back-end loaded.
• Pricing is under pressure. Q2 revenue was only $508M despite 10M EyeQ units, because ASP came in below expectations due to China OEM export mix, and management flagged a 2H SuperVision shipment step-down as inventory is consumed and sample timing slips to 2027.
• Valuation still assumes better growth than current fundamentals support. MBLY trades at 3.2x sales versus peers at 1.1x, while FY2025 revenue grew just 2.9% and FY2025 EPS was -$0.48.
• The FY26 profit raise is flattered by incentives. Of the new $395M adjusted operating income midpoint, $180M to $200M comes from the R&D incentive benefit, and management said Q3 incentive contribution will drop significantly versus Q2 because Q2 included a retroactive catch-up.

Valuation & Price Target

Engine price target $4.67 (-38.6% vs current), Low confidence.

• P/S Multiple: $2.84 (36% weight)
• Quality-adjusted: $8.34 (20% weight)
• DCF: $3.58 (6% weight)

This rating aligns with the quant baseline SELL (Low conviction). The key reason not to fight the model is that the valuation still looks too high relative to the actual forward path: 3.2x sales versus peer average 1.1x, with FY2025 revenue growth of 2.9%, Q3 FY26 revenue guided down 5% to 6% YoY, and a large share of the FY26 profit uplift coming from the $180M to $200M R&D incentive rather than from cleaner operating leverage. The strongest counterargument is management's recent earnings execution, including 8 straight EPS beats, no debt, positive FCF, and evidence that OEM share is improving. That keeps conviction low rather than high. Sell-side consensus remains far more bullish, but that is low-signal context here and does not square with the combination of premium sales multiple, negative near-term growth, and delayed advanced-system timing.

Risk Assessment

Risk score 37/100 (Low). The biggest risk to a bearish call is that Mobileye converts its 39M+ FY26 EyeQ unit trajectory and 2027 ASP tailwinds into a faster earnings inflection than the market expects, especially if the $180M to $200M R&D credit proves durable.

The Bottom Line

MBLY rates SELL, Low conviction. The company is better than the stock's recent tape suggests, but the stock is still richer than the company's current growth and pricing profile justify. The decisive facts are 3.2x sales versus 1.1x peers, Q3 revenue guided down 5% to 6% YoY, and a profit upgrade heavily supported by $180M to $200M of incentives. A turn to BUY would require evidence that 2027 programs are firming, ASP is recovering, and growth is accelerating beyond low-single digits without relying on accounting or incentive tailwinds.